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ABSTRACT 
We present the case of a 77 year old male patient with metastatic pancreatic neuroendocrine tumor (NET). The 
patient was initially treated by extensive surgical resection that however, led to severe complications with delayed 
recovery. During follow-up, a number of new liver metastases were detected, one of which was in segment I with 
impending compression of the inferior vena cava. Due to age and general condition of the patient, instead of further 
surgical treatment, the patient received four cycles of 177Lu-DOTATOC resulting in an overall partial response 
with successful tumor reduction in liver segment I, resolving an impending compression of vena cava. 
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INTRODUCTION 
Liver metastasis commonly develops in 
gastroenteropancreatic neuroendocrine tu-
mors (NETs) and affects patients’ survival to 
a high extent. Various symptoms may present 
due to tumor pressure effect or extensive re-
placement of normal liver parenchyma (John 
and Davidson, 2012). Extravascular compres-
sion of inferior vena cava (IVC) by tumors is 
a rare but serious condition that can lead to 
increased intra-abdominal pressure, throm-
bosis, lower limb edema, liver and kidney 
damage and reduced cardiac venous return, 
causing hemodynamic disturbances and even 
life threatening hypovolemic shock 
(Mohammed et al., 2018; Sonin et al., 1992). 
Proper management of venous obstruction 
and prevention of potential thrombosis is a vi-
tal palliative care besides treating the under-
lying malignancy, leading to a decline in mor-
bidity and mortality (Friedman et al., 2017). 
Even though radical surgery of the primary 
tumor and the liver metastasis is the main cu-
rative strategy, masses are not always resec-
table due to extended size, vast local invasion 
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to critical surrounding structures and patient’s 
underlying conditions. 
Herein, we describe a case of moderately 
differentiated pancreatic NET with progres-
sive liver metastasis and impending IVC com-
pression, 2.5 years after radical surgery.  
 
CASE REPORT 
A 77 year old male patient was diagnosed 
in his local hospital with non-functional NET 
of the pancreatic tail with liver metastasis and 
malignant vascular and lymphatic invasions 
in 2014.  
He underwent a resection of the primary 
pancreatic tumor, accompanied by partial re-
section of the posterior gastric wall, splenec-
tomy, cholecystectomy and resection of the 
liver segment IVb. A histological examina-
tion demonstrated moderately differentiated 
NET, stage pT4 pN0 L1, V1, R0, G3 and Ki-
67 of 11 %. Multiple postoperative complica-
tions, including pancreatic fistula, papillary 
stenosis, several episodes of pneumonia with 
pleural effusion, abscess in former spleen site, 
cardiac arrhythmia and a transient ischemic 
attack (TIA) led to long-term Intensive care 
unit admission.  
Seven month post-surgery 68gallium DO-
TATOC PET/CT showed a focal tracer up-
take in the liver segment I, without corre-
sponding lesion on CT or MRI. Approxi-
mately 2.5 years after, ultrasound exam and 
MRI demonstrated multiple liver metastasis 
directly adjacent to the IVC (Figure 1A). In 
addition, an intense uptake (SUV max: 60.78) 
was detected on the 68gallium DOTATOC 
PET/CT, confirming progressive liver metas-
tasis (Figure 2A).  
The patient was referred to our hospital 
for further assessment and treatment. Due to 
extensive metastasis adjacent to the IVC, high 
tracer uptake and patient’s general condition 
including history of several post operation 
complications, cardiac diseases and age, 
PRRT was recommended by the interdiscipli-
nary tumor board. 
The patient was given 4 cycles of 177Lu-
DOTATOC with cumulative activity of 28.8 
GBq, every 2 months. To prevent nephrotox-
icity, an amino acid infusion was given in 
each cycle. No serious side effects were ob-
served during or after the therapy and labora-
tory data on kidney and bone marrow function 
were normal. The scintigraphic control per-
formed after the therapies revealed a good up-
take to the lesions.  
 
 
 
Figure 1: (A): MRI, nine weeks prior to the therapy, revealing the metastatic mass in the liver with an 
impending IVC compression (IVC diameter: 18.4 x 8.1 mm), (B): CT scan, Twelve months after last 
PRRT cycle with significant decompression of the vein (IVC diameter: 30.9 x 19.9 mm) 
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Figure 2: 68gallium DOTATOC PET/CT; (A): Seven weeks prior to the therapy, revealing intense tracer 
uptake in the liver lesion (SUV max: 60.78), (B): Twelve months after last PRRT cycle with significant 
decreased tracer uptake (SUV max: 8.62) 
 
 
 
PET/CT scans 4, 6 and 12 months after the 
last PRRT cycle revealed further decreasing 
tracer uptake in liver segment I (SUV max: 
7.82) and a very good palliative therapy out-
come, in particular with significant reduction 
of the tumor mass and decompression of the 
ICV (30.9 x 19.9 mm vs. 18.4 x 8.1 mm) (Fig-
ure 2B). Even though the patient did not have 
cholestasis symptoms, a declining pattern to-
ward normal was observed in gamma-glu-
tamyl transferase (223 vs. 99 U/L) and alka-
line phosphatase (195 vs. 145 U/L) serum lev-
els, reflecting improvement in biliary tree 
drainage one year after the therapy. 
 
DISCUSSION 
A significant number of pancreatic NET 
patients present with locally advanced disease 
or distant metastasis. Selecting the most ap-
propriate treatment strategy can be a clinical 
dilemma in some patients. Performing sur-
gery in cases similar to our patient with old 
age, poor general condition and several post 
operation complications does not seem to be 
beneficial (Norton et al., 2011). Current inter-
national guidelines recommend using PRRT 
only as second or third line therapy after fail-
ure of first line medical therapies (Pavel et al., 
2012). However, in some cases medical treat-
ment may be insufficient for management of 
extensive tumor in critical locations. Thus, in-
dividualized selection of alternative treatment 
options for such cases seems necessary. In 
such cases, the current German practice 
guideline recommends considering 177Lu-Do-
tatate as first-line treatment based on individ-
ualized interdisciplinary decision-making by 
a tumor board (Rinke et al., 2018).  
 
CONCLUSION 
We reported successful palliative treat-
ment with 177Lu-DOTATOC in a case of pan-
creatic NET recurrence with extensive unre-
sectable liver metastasis and impending IVC 
compression. PRRT can be considered as a 
beneficial treatment strategy in such patients 
with inoperable extensive masses adjacent to 
critical vessels. 
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